Michael Shuler,
Samuel B. Eckert Professor of Engineering,
Cornell University, President Hesperos, Inc.
Michael L. Shuler is the Eckert Professor of Engineering, Emeritus in the Meing Department of Biomedical Engineering and in the Smith School of Chemical and Biomolecular Engineering at Cornell University, and was director of Cornell’s Nanobiotechnology Center. Shuler has degrees in chemical engineering (BS, Notre Dame, 1969 and Ph.D., Minnesota, 1973) and has been a faculty member at Cornell University since 1974. Shuler’s research includes development of “Body-on-a-Chip” for testing pharmaceuticals for toxicity and efficacy, creation of production systems for useful compounds, such as paclitaxel from plant cell cultures, and construction of whole cell models relating genome to physiology. Shuler is CEO and President of Hesperos, a company founded to implement the “Body-on-a-Chip” system. Shuler and F. Kangi have authored a popular textbook, “Bioprocess Engineering; Basic Concepts” now in its third edition. He has an honorary doctorate from the University of Notre Dame. Shuler has been elected to the National Academy of Engineering and the American Academy of Arts and Science and is a fellow of numerous professional societies.
Making Microphysiological Systems (MPS) Useful
Wednesday, 26 July 2023 at 09:00
Add to Calendar ▼2023-07-26 09:00:002023-07-26 10:00:00Europe/LondonMaking Microphysiological Systems (MPS) UsefulMicrophysiological Systems 2023: A Deep Dive into Technologies and Applications in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com
We will discuss briefly some of the origins and history of multiorgan MPS development as well as current applications of the technology. The differences between multiorgan (e.g., "body-on-a chip") and single organ models will be discussed. Examples of current uses will be described including the use of MPS data to gain FDA approval for clinical trials. Current "Body-on-a-Chip" systems combine organized tissue/organ mimics with the techniques of microfabrication based on PBPK (Physiologically Based?Pharmacokinetic) models. These systems are "self-contained" and do not require external pumps, leading to "pumpless systems" which reduce system cost and improve?operational reliability. While the fluid (or blood?surrogate) in these systems can be sampled directly to allow measurement of?concentrations of drug,?metabolites or biomarkers, they can also be interrogated in situ to determine functional responses such as electrical response, force generation, or barrier?integrity . The blood?surrogate can be made to be as a serum-free, chemically defined medium facilitating interpretations of responses that are more mechanistic than with serum?containing media. We have constructed models of barrier tissues and have integrated them into a multiorgan system. A key advantage of this "Body-on-a-Chip" approach is that we can predict both human efficacy and toxicity of a drug or drug combination in preclinical trails, A Hesperos system has been used as the sole source of efficacy data for an IND application by Sanofi for a drug currently in a Phase 2 clinical?trial?demonstrating that these systems are beginning to have direct commercial impact as well as helping companies evaluate drug leads.
Add to Calendar ▼2023-07-26 00:00:002023-07-27 00:00:00Europe/LondonMicrophysiological Systems 2023: A Deep Dive into Technologies and ApplicationsMicrophysiological Systems 2023: A Deep Dive into Technologies and Applications in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2023-07-26 09:00:002023-07-26 10:00:00Europe/LondonMaking Microphysiological Systems (MPS) UsefulMicrophysiological Systems 2023: A Deep Dive into Technologies and Applications in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com
